Neostigmine Cooper (Neostigmine Methylsulfate)

Neostigmine methylsulfate inhibits the enzyme acetylcholinesterase, which normally breaks down acetylcholine. By blocking this enzyme, the drug raises acetylcholine levels at neuromuscular junctions, enhancing cholinergic transmission and promoting muscle contraction and gastrointestinal movement.

The specific dose of Neostigmine Cooper is determined by the prescribing clinician based on the indication, patient weight, renal function, and clinical response. Dosage regimens are individualized and should follow the prescriber's instructions.

Safety data for Neostigmine methylsulfate in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Neostigmine is a reversible anticholinesterase with a relatively rapid onset and short duration, making it suitable for intra‑operative reversal of neuromuscular blockade. Compared with longer‑acting agents such as pyridostigmine, Neostigmine provides quicker, controllable effects but may require more careful monitoring for cholinergic side effects.

Neostigmine Cooper should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability.

The drug is supplied as an injectable solution and can be given intramuscularly, intravenously, or subcutaneously. Administration technique, site, and rate are determined by the treating clinician according to the clinical situation.

Serious risks include bradycardia, severe hypotension, bronchospasm, cholinergic crisis, and rare allergic reactions such as anaphylaxis. Prompt recognition and supportive measures are essential if any of these events occur.

Neostigmine Cooper is contraindicated in patients with known hypersensitivity to neostigmine or other anticholinesterases, those with severe cardiac conduction disorders without appropriate monitoring, and individuals with active cholinergic poisoning. Clinical judgment is required for all other cases.